Biotechnology

Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

GEN (Genetic Engineering & Biotechnology News) Alex Philippidis

StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?

While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.

Read at GEN (Genetic Engineering & Biotechnology News)

STAT Biotech Adam Feuerstein

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

Read at STAT Biotech

The Guardian World Nicola Davis Science correspondent

Hundreds of children in England prescribed weight-loss jabs, figures show

Exclusive: investigation finds prescriptions for children under 12, as experts stress need for specialist supervision and long-term monitoring Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some younger than 12, the Guardian can reveal. GLP-1 medications were initially developed to help people with type 2 diabetes control their blood sugar levels, but have since become a popular slimming aid, with products such as Wegovy and…

Read at The Guardian World

SCMP China Ling Xin

Chinese scientists fired after child dies in world’s first brain gene-editing attempt

The world’s first attempt to edit genes inside a child’s brain, which killed a six-year-old girl in Shanghai last year, has led to the firing of scientists following an official investigation that found they had broken research rules and taken money from her family. The investigation, ordered by the Communist Party’s Shanghai municipal committee and the local government, concluded on Friday that the researchers had not shared worrying results from monkey tests with the…

Read at SCMP China

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression

Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma in situ, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies.

Read at GEN (Genetic Engineering & Biotechnology News)

Ars Technica Beth Mole

Millions of Americans are not taking their GLP-1 drugs as prescribed

Cost and access barriers are pushing people to modified use and unapproved versions.

Read at Ars Technica

GeekWire Startups Lisa Stiffler Startups

Araceli raises $4.5M for drug discovery tools aimed at reducing animal testing

Oregon-based Araceli Biosciences raised $4.5 million to commercialize cell-imaging tools that help researchers test potential drugs using human cells, with the aim of reducing reliance on animal studies while producing more relevant results.

Read at GeekWire Startups

GEN (Genetic Engineering & Biotechnology News) Julianna LeMieux, PhD

How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital

A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant Enterococcus faecium in Danish hospitals between 2012 and 2020.

Read at GEN (Genetic Engineering & Biotechnology News)

The Hill Teddy Grant Geopolitics

DJ Khaled shares he lost 90 pounds with help of GLP-1 drug

In October 2025, Khaled experienced a health scare at a concert, which led to a lifestyle change.

Read at The Hill

GEN (Genetic Engineering & Biotechnology News) Kathy Vuksanaj

Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave

In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.

Read at GEN (Genetic Engineering & Biotechnology News)

STAT Biotech Meghana Keshavan

STAT+: HHS plans funding for research into ibogaine for PTSD

The Trump administration will funnel up to $4.9 million into supporting research into ibogaine, a psychedelic that’s drawn interest as a potential treatment for PTSD and addiction.

Read at STAT Biotech

BioPharma Dive BioPharma Dive staff

Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties

Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

This week in charts: Brain drugs are back on venture’s minds

Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.

Read at BioPharma Dive

STAT Biotech Elaine Chen

STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say

With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.

Read at STAT Biotech

Green Queen (alternative protein) Anay Mridul

India’s Symbiotec Pharmalabs to Produce Precision-Fermented Protein for EU Partner in 10-Year Deal

4 Mins ReadIndian biotech firm Symbiotec Pharmalabs has signed a 10-year deal to serve as a contract manufacturer for a European company’s precision-fermented protein. Shoring up India’s biomanufacturing prowess, Symbiotec Pharmalabs has expanded its contract manufacturing services for a European innovator in alternative proteins. The biotech firm has signed a 10-year take-or-pay agreement with an unnamed European

Read at Green Queen (alternative protein)

Asia Times Damien Ng Geopolitics

China’s demographic challenge becoming its biotech advantage

Is biotechnology becoming the next space race? The Biotechnology Innovation Organization (BIO) appears to think so. This month, it urged Washington to adopt a comprehensive national biotechnology strategy, warning that China is rapidly gaining ground in an industry now viewed as critical to economic competitiveness and national security. The United States and China have spent

Read at Asia Times

BioPharma Dive Gwendolyn Wu

Windward prices $175M IPO to advance China-licensed lung drugs

The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.

Read at BioPharma Dive

South China Morning Post Xinmei Shen Geopolitics

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists…

Read at South China Morning Post

GEN (Genetic Engineering & Biotechnology News) Savannah Wiegel

Reference Genomes of Malaria-Causing Plasmodium Parasites Completed

Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort

A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Uduak Thomas

Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint

The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.

Read at GEN (Genetic Engineering & Biotechnology News)

BioPharma Dive Jonathan Gardner

Blackstone bets $1.5B on Pfizer’s obesity drug

The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

Read at BioPharma Dive

STAT Biotech Meghana Keshavan

STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment

Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.

Read at STAT Biotech

BioPharma Dive Kristin Jensen

Bristol Myers research chief to depart in ‘evolution’ of company’s structure

Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.

Read at BioPharma Dive

The Hill Sreedhar Potarazu, opinion contributor Geopolitics

The risk of blindness from GLP-1 drugs is too serious to ignore

When a medication is prescribed to millions of people, even an uncommon complication can affect a substantial number of individuals.

Read at The Hill

BioPharma Dive Kelly Bilodeau

The FDA has over 1k open jobs — and the staffing shortage is hitting pharma

The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

Read at BioPharma Dive

The Decoder Alan Truly SI

Google Deepmind shifts genomics AI from bulk tissue predictions to single cell type resolution with AlphaGenome 2

Google Deepmind has unveiled AlphaGenome 2, an AI model that analyzes genetic variants for individual cell types rather than across bulk tissue. Trained on more than 107 million cell profiles, it identifies nearly twice as many disease-relevant gene changes as its predecessor. The model is available for noncommercial research through an API and is set to be integrated into Google's agentic platform Antigravity. The article Google Deepmind shifts genomics AI from bulk tissue…

Read at The Decoder

STAT Biotech Adam Feuerstein

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: What to know about Biogen’s big lupus study readout

Biogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.

Read at STAT Biotech

South China Morning Post Xinmei Shen Geopolitics

Former ByteDance AI scientist touts drug-discovery model that tops world leaders

A former ByteDance artificial intelligence scientist’s new venture has released a life sciences AI model that the firm claims outperforms state-of-the-art systems, intensifying the increasingly crowded competition in AI-driven drug discovery. Geodesic Intelligence’s NovaAtom-Lite, an AI model designed to predict the structures and interactions of biomolecules, topped a third-party benchmark in several drug discovery tasks, founder Quanquan Gu said on social media on…

Read at South China Morning Post

Older stories